Life settlements can be a good investment — but only for a specific investor profile. The documented case is strong: institutional research points to historical target IRRs in the 8–12% range, minimal correlation to equity markets, and actuarially driven performance that held up through multiple economic cycles. The documented limitations are equally real: illiquidity spanning 5–10 years, accreditation requirements that exclude most retail investors, fund-level valuation issues documented in academic research, and sensitivity to life expectancy estimation accuracy. Conning's 2025 strategic study titled "A Pause for Now" captures the current market mood honestly — growth continues, but not without friction. For accredited investors with defined allocation budgets and long holding periods, life settlements are a legitimate portfolio tool. For most other investor profiles, they are not.
The question in the title deserves a real answer, not a sales pitch. I've spent more than a decade working in and around life settlement investments, and I've watched the asset class perform well for investors who fit the profile and poorly for investors who didn't. The difference isn't typically about the asset itself — it's about whether the investor understood what they were buying and whether their capital position matched what the asset requires. What I want to do here is lay out the actual evidence on both sides, with real industry data, and let you make the evaluation yourself.
What the industry data actually says in 2026
Before any verdict, here's what credible sources have actually documented about the asset class. These aren't marketing numbers — they're the figures institutional research firms and industry associations have published based on real transaction data.
- Target IRR range: 8–12% net to investor. Institutional research firms including Resonanz Capital and independent asset managers consistently cite 8–12% as the historical target IRR range for institutionally managed portfolios. Individual transactions can vary widely above and below this range.
- Market size: $4.5B annual face value (2023). According to industry data, investors acquired approximately 3,400 policies totaling $4.5 billion in face value in 2023. Conning's 2025 strategic study projects annual volumes reaching approximately $4.6B going forward, against an estimated $224B in gross addressable market supply.
- Correlation to equity markets: historically low. Returns are driven by mortality outcomes rather than market sentiment. Industry research documents correlations near zero against S&P 500 and diversified equity indices over multi-year periods. This is the core structural argument for the asset class.
- Institutional adoption is growing. A Managing Partners Group survey of 100 investment professionals globally found that 64% predict increased investment in life settlement funds over the next five years, with 86% expecting wealth managers and pension schemes to enter the asset class for the first time.
- Regulatory framework is mature. 43 U.S. states plus Puerto Rico have specific life settlement legislation, with state insurance departments providing oversight. The Grigsby v. Russell Supreme Court case (1911) established the legal foundation for transferability.
- Fund-level valuation issues have been documented. Peer-reviewed academic research analyzing 11 life settlement funds found that a majority appeared to overstate NAVs relative to comparable transactions. This is a real, documented limitation of the open-end fund format specifically.
Conning estimates the average annual gross market potential for life settlements at $224 billion in addressable supply — against actual annual transaction volumes of approximately $4.5B. The gap between supply and transaction activity suggests the market is structurally under-penetrated, with institutional adoption continuing but not yet at scale. Reference: Conning 2025 Strategic Study.
Strengths and limitations — honest scorecard
This is the evaluation I'd walk any serious investor through. Life settlements have genuinely distinctive strengths, and they have genuinely meaningful limitations. Both deserve to be on the table before any allocation decision is made.
What makes the case for
- Low correlation to equity markets. Returns driven by mortality outcomes, not market sentiment. Zero or near-zero historical correlation against S&P 500.
- Actuarially modeled returns. Cash flows follow statistical distributions built on Social Security Administration mortality data and insurance industry underwriting experience.
- 8–12% target IRR historical range. Equity-like returns with volatility profile closer to fixed income at the portfolio level.
- Resilience through downturns. Performance held up during 2008 financial crisis, 2020 pandemic shock, and 2022 market volatility — returns did not move with broader markets.
- Growing institutional credibility. Pension funds, endowments, family offices increasingly allocating. Fund structures have matured and regulatory frameworks are well-established.
- Transferable legal asset. Established since 1911 Supreme Court precedent. State-level regulation in 43 U.S. states plus Puerto Rico.
What makes the case against
- Illiquidity is not optional. Capital typically committed for 5–10 years in direct ownership or closed-end funds. Secondary markets for exit exist but are limited and discount heavily.
- Accreditation required for most structures. $1M+ net worth or $200K+ annual income excludes most retail investors from direct ownership and Reg D fund offerings.
- High minimums limit accessibility. Direct ownership typically $100K+ per policy. Reg D funds often $100K–$500K minimum. Retail-accessible paths (Reg A+, interval funds) come with their own trade-offs.
- Fund-level valuation issues documented. Academic research shows open-end funds have historically overstated NAV, affecting fee calculations and redemption pricing. Closed-end funds partially address this but don't eliminate it.
- LE estimation accuracy is the whole game. If life expectancy reports systematically understate actual longevity, realized IRRs compress significantly. Underwriting quality is the single largest input to outcomes.
- Tax treatment mostly ordinary income. Under IRS Revenue Ruling 2009-14, most of the gain is taxed at ordinary rates rather than long-term capital gains — reducing after-tax returns meaningfully for investors in high brackets.
This is the honest picture. Neither the strengths nor the limitations cancel each other — they coexist in the same asset class, which is why the right answer to "is this a good investment?" is always conditional on the specific investor asking. The asset itself doesn't change; the investor profile does.
How life settlements compare to other alternatives
The fair comparison isn't "life settlements vs. the S&P 500" — it's life settlements against other alternatives investors might consider for the same portfolio slot. Here's how the asset class lines up against the comparable alternatives most accredited investors evaluate.
| Asset class | Target return | Correlation to equities | Liquidity |
|---|---|---|---|
| Life settlements | 8–12% target IRR | Near-zero historically | Very illiquid (5–10 yr) |
| Private credit | 7–10% yields | Moderate | Illiquid (3–7 yr) |
| Non-traded REITs | 5–8% yields | Moderate to high | Illiquid (redemption gates) |
| Private equity | 15–20% target IRR | Moderate to high | Very illiquid (7–10 yr) |
| Hedge fund strategies | 4–10% depending on strategy | Variable | Limited (quarterly/annual) |
| Publicly traded REITs | 4–8% total return | High | Daily |
| Investment-grade corporate bonds | 4–6% yield | Moderate (rates) | Daily |
Life settlements' distinctive position in this comparison is the combination of mid-range target returns (8–12%) with near-zero equity correlation. Private equity offers higher target returns but with correlation to economic cycles. Private credit and non-traded REITs offer more liquidity but with higher equity correlation. The specific portfolio problem life settlements solve is uncorrelated yield — and that's a problem worth solving for investors whose existing allocations are heavily exposed to equity market risk.
See current vetted policy inventory
HYV gives accredited investors direct access to individual vetted life settlement policies with complete documentation. See what matches your investment horizon, return target, and risk profile.
Browse ListingsWho they're a good investment for — and who they're not
Rather than a vague "it depends," here are the three investor profiles I actually see in practice, and an honest verdict on whether life settlements fit each one.
Accredited investor with alternative allocation
$2M+ investable assets, has defined 10–20% alternative bucket, long investment horizon, existing allocations heavy in equities or private credit.
Retiree seeking income stability
Accredited, conservative investor in or near retirement, prioritizing income and capital preservation, uncomfortable with equity volatility.
Mid-career investor with growth focus
Non-accredited or newly accredited, under 40, no significant alternative allocation yet, still building toward larger financial goals (home purchase, kids' college).
The pattern across these three profiles is consistent: life settlements fit investors who have already completed their capital accumulation phase and are now managing a diversified portfolio with defined alternative allocations. They don't fit investors still in accumulation mode who need equity-market growth and capital flexibility. Both profiles are legitimate — they just aren't the same investor.
The 2026 context — "A Pause for Now"
Conning's 2025 strategic study on the asset class carries a telling subtitle: "A Pause for Now." That's an honest characterization of where the market actually is. Growth continues, institutional adoption continues, and the underlying drivers (aging demographics, life insurance policyholder liquidity needs, investor search for uncorrelated yield) remain strong. But the asset class is not experiencing runaway growth — it's consolidating at current scale while the industry works through documented structural issues.
What's driving the pause
- Education and transparency gaps. Conning's survey explicitly cited "the need for greater education, historical return data, and transparency regarding fees" as barriers to broader institutional adoption. These aren't fatal issues, but they're real frictions that slow capital deployment.
- Open-end fund valuation issues. The documented NAV overstatement problem in open-end structures creates hesitation among sophisticated allocators who recognize the structural issue. Closed-end structures are gaining share as a result.
- Aggressive institutional pricing compresses returns. Institutional capital has bid up the tertiary market, which compresses yields for investors entering at current pricing levels. The 8–12% target IRR range today is at the lower end of what the asset class produced a decade ago.
- Regulatory stability but not expansion. The state-by-state regulatory framework is mature, but there's no meaningful federal harmonization or expansion. This keeps the market structurally fragmented compared to more standardized alternatives.
What's still working
Despite the pause, the core economic thesis remains intact. An aging U.S. population with significant life insurance coverage creates ongoing policy supply. Institutional investors continue to seek uncorrelated yield in an environment where traditional alternatives are increasingly crowded. Regulatory frameworks, while state-fragmented, are stable and well-tested. And the structural math — buying future death benefits at a discount to expected value — continues to produce returns for well-underwritten portfolios.
Browse what's available today
HYV's marketplace lists vetted individual policies with complete documentation. See what current inventory looks like at today's market pricing — the best way to evaluate whether this asset class fits your specific portfolio.
A practical evaluation framework for your situation
If you're genuinely evaluating whether this asset class fits your portfolio, work through these questions. They're the same ones I'd ask on an initial call with any investor considering an allocation.
- Do I meet accredited investor requirements? $1M+ net worth excluding primary residence, $200K+ annual income (individual) or $300K+ joint, or a qualifying professional securities license. If not, most direct ownership and Reg D structures are closed — focus evaluation on retail-accessible alternatives instead.
- Do I have defined alternative allocation capacity? Life settlements typically fit inside a broader alternative investments sleeve (10–25% of total portfolio). If you don't have that allocation defined or aren't sure how much of your portfolio should be in alternatives, work on that question first with a qualified advisor.
- Can I genuinely commit capital for 5–10 years? Not "probably" — genuinely. Capital committed to life settlements is functionally inaccessible for the hold period. If there's meaningful probability you'll need the money before then, this is the wrong fit regardless of how attractive the returns look.
- Am I comfortable with mortality-linked returns? Some investors find the underlying mechanic (returns correlated with specific person's passing) psychologically uncomfortable. That's a legitimate consideration. If it bothers you meaningfully, other non-correlated asset classes exist.
- Do I have tax-efficient account structures for this? Life settlement returns are mostly ordinary income. Holding through tax-advantaged structures (self-directed IRA, certain insurance wrappers) can significantly improve after-tax outcomes — but these structures require specific setup and are not available to all investors.
- Have I done platform-level due diligence? The asset class quality depends heavily on the specific platform, fund manager, or provider the investor transacts through. A good asset in a bad vehicle can still produce poor outcomes. Evaluate the delivery mechanism with the same rigor as the asset class itself.
If you answered yes to all six questions — accredited, defined allocation, true long-horizon capital, comfortable with the mechanic, tax-efficient structures available, platform-level due diligence complete — then life settlements can be a genuinely good investment for your specific situation. If you couldn't answer yes to one or more, the honest answer is that the asset class isn't the right fit right now, regardless of how strong the industry data looks.
Industry research from Conning's 2025 Life Settlements Strategic Study and Resonanz Capital's institutional analysis covers the structural and performance fundamentals. For regulatory context, FINRA's investor bulletin on life settlements covers consumer protection perspective. For peer-reviewed academic work on fund valuation, the research published in journals covering alternative investment analysis addresses open-end structure limitations. Individual evaluation should always include consultation with a qualified financial advisor familiar with your specific portfolio and tax situation.
Direct ownership access through HYV
If you're an accredited investor with defined alternative allocation capacity and long-horizon capital, HYV's marketplace offers direct access to individually vetted policies — complete documentation, transparent fees, no fund wrappers.
Frequently asked questions
Are life settlements a scam?
No — life settlements are a legitimate, regulated alternative asset class with decades of institutional investment history. The legal framework traces to the 1911 Supreme Court case Grigsby v. Russell, and today 43 U.S. states plus Puerto Rico regulate the industry through state insurance departments. Credible institutional research firms including Conning, Resonanz Capital, and peer-reviewed academic journals have documented the asset class. That said, like most alternative investments, life settlements have attracted bad actors over the years — particularly in fractional retail offerings that were later deemed unregistered securities. The asset class itself is legitimate; platform selection and due diligence matter enormously.
What's the realistic return I should expect from life settlements?
Institutional target IRR ranges cited by industry research firms are typically 8–12% net to investor, with individual transactions varying widely above and below that range. Realized returns depend heavily on life expectancy estimation accuracy, fee structure of the vehicle used, and portfolio diversification quality. Single-policy ownership has much higher variance than diversified portfolios. Fund structures compress gross returns by their fee stack. The honest expectation: a well-executed allocation at current market pricing, delivered through a transparent structure, should produce returns in the 7–10% net-of-fees range at the portfolio level over the hold period. Returns below or above this range are both possible and both have occurred historically.
How did life settlements perform during the 2020 pandemic?
Performance was largely uncorrelated to equity market disruption, which is what the asset class is structured to deliver. Equity markets experienced significant volatility in March 2020, followed by sustained recovery. Life settlement portfolios continued producing cash flows based on underlying mortality outcomes rather than market sentiment. COVID-related excess mortality did create some short-term variance at the individual portfolio level, but the diversified institutional portfolios held up well. The 2020 experience is generally cited as supporting evidence for the low-correlation thesis — portfolios did not move with public markets during the most volatile equity period of the past decade.
Is 2026 a good time to invest in life settlements?
For investors who fit the profile, current market conditions are reasonable but not exceptional. Conning's 2025 study titled "A Pause for Now" captures the mood honestly — growth continues, institutional adoption is stable, but aggressive tertiary market pricing has compressed yields compared to earlier years. Current target IRRs sit at the lower end of the 8–12% historical range. This isn't a reason to avoid the asset class, but it's a reason to model conservative base-case returns rather than optimistic ones. The timing question matters less than the investor-fit question for long-horizon allocations — if you're committing capital for 5–10 years, entry-point timing is less important than underwriting quality.
What are the biggest risks I need to understand?
Four primary risks stand out. First, longevity risk — insureds living longer than projected compress realized IRRs, and individual-policy outcomes have high variance. Second, illiquidity risk — committed capital is functionally inaccessible for the hold period, and exit options exist but discount heavily. Third, platform or manager risk — the vehicle you transact through affects outcomes as much as the asset class itself, and documented fund-level valuation issues have existed. Fourth, regulatory risk — while the framework is mature, state-level regulation can change, and federal securities treatment of fractional interests has evolved meaningfully (see 2025 PWCG ruling). None of these risks are disqualifying for well-positioned investors, but they should all be understood before committing capital.
Are life settlements better than bonds or dividend stocks?
They're not directly comparable — the asset classes serve different purposes in a portfolio. Bonds provide liquid, fixed-income exposure with daily marketability and interest-rate sensitivity. Dividend stocks provide equity market exposure with income characteristics and equity-market correlation. Life settlements provide illiquid, uncorrelated yield driven by mortality outcomes rather than market dynamics. A balanced portfolio often includes all three serving different roles rather than treating them as substitutes. For accredited investors with sufficient capital and defined allocation buckets, life settlements can complement traditional fixed-income and dividend equity exposure rather than replace them. Treating them as mutually exclusive is usually a sign the investor hasn't clearly defined what each asset class is doing in their portfolio.
How much of my portfolio should be in life settlements?
Institutional allocators typically sleeve 2–8% of total portfolio into life settlements specifically, within a broader alternative investments bucket that might represent 15–30% of total portfolio. For individual accredited investors, similar ranges apply — 2–8% of investable assets specifically to life settlements is a reasonable starting range, with the exact figure depending on existing allocations and overall portfolio objectives. Higher concentrations (10%+) begin creating concentration risk in an illiquid asset class that's hard to rebalance. Lower concentrations (under 2%) often don't move the portfolio needle enough to justify the due diligence effort. Always work with a qualified advisor familiar with your full financial picture before setting specific allocation targets.
